BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 34076961)

  • 1. How limited molecular testing can also offer diagnostic and prognostic evaluation of thyroid nodules processed with liquid-based cytology: Role of TERT promoter and BRAF V600E mutation analysis.
    Dell'Aquila M; Fiorentino V; Martini M; Capodimonti S; Cenci T; Lombardi CP; Raffaelli M; Pontecorvi A; Fadda G; Pantanowitz L; Larocca LM; Rossi ED
    Cancer Cytopathol; 2021 Oct; 129(10):819-829. PubMed ID: 34076961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population.
    Lee SE; Hwang TS; Choi YL; Han HS; Kim WS; Jang MH; Kim SK; Yang JH
    Thyroid; 2016 Jul; 26(7):901-10. PubMed ID: 27184112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
    Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
    Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical implication of highly sensitive detection of the BRAF V600E mutation in fine-needle aspirations of thyroid nodules: a comparative analysis of three molecular assays in 4585 consecutive cases in a BRAF V600E mutation-prevalent area.
    Lee ST; Kim SW; Ki CS; Jang JH; Shin JH; Oh YL; Kim JW; Chung JH
    J Clin Endocrinol Metab; 2012 Jul; 97(7):2299-306. PubMed ID: 22500044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.
    Bae JS; Kim Y; Jeon S; Kim SH; Kim TJ; Lee S; Kim MH; Lim DJ; Lee YS; Jung CK
    Diagn Pathol; 2016 Feb; 11():21. PubMed ID: 26857243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of BRAF c.1799T > A (p.V600E) mutation using residual routine fine-needle aspiration specimens of papillary thyroid carcinoma.
    Zhao H; Zhang ZH; Zhou B; Xiao T; Pan QJ; Guo HQ
    Diagn Cytopathol; 2015 Oct; 43(10):786-90. PubMed ID: 26152656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrating Molecular Testing in the Diagnosis and Management of Children with Thyroid Lesions.
    Ballester LY; Sarabia SF; Sayeed H; Patel N; Baalwa J; Athanassaki I; Hernandez JA; Fang E; Quintanilla NM; Roy A; López-Terrada DH
    Pediatr Dev Pathol; 2016; 19(2):94-100. PubMed ID: 26366474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic Value and Challenges of BRAF V600E Molecular Testing and Thyroid Fine-Needle Aspiration Cytology: A Retrospective Study from a Tertiary Institution in Southern Hunan Province, China.
    Lan Z; Yang F; Zhang J; Lan Y; Li H; He R
    Acta Cytol; 2023; 67(6):629-638. PubMed ID: 37708867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of the BRAF(V600E) mutation in fine needle aspiration cytology of thyroid papillary microcarcinoma cells selected by manual macrodissection: an easy tool to improve the preoperative diagnosis.
    Marchetti I; Iervasi G; Mazzanti CM; Lessi F; Tomei S; Naccarato AG; Aretini P; Alberti B; Di Coscio G; Bevilacqua G
    Thyroid; 2012 Mar; 22(3):292-8. PubMed ID: 22181337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF (V600E) mutation analysis on liquid-based cytology-processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma.
    Rossi ED; Martini M; Capodimonti S; Lombardi CP; Pontecorvi A; Vellone VG; Zannoni GF; Larocca LM; Fadda G
    Cancer Cytopathol; 2013 Jun; 121(6):291-7. PubMed ID: 23192956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Coexistent BRAF
    Moon S; Song YS; Kim YA; Lim JA; Cho SW; Moon JH; Hahn S; Park DJ; Park YJ
    Thyroid; 2017 May; 27(5):651-660. PubMed ID: 28181854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy.
    Liu R; Xing M
    Endocr Relat Cancer; 2014 Oct; 21(5):825-30. PubMed ID: 25121551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF (V600E) Harboring Pediatric Papillary Thyroid Carcinomas.
    Onder S; Ozturk Sari S; Yegen G; Sormaz IC; Yilmaz I; Poyrazoglu S; Sanlı Y; Giles Senyurek Y; Kapran Y; Mete O
    Endocr Pathol; 2016 Jun; 27(2):153-61. PubMed ID: 26951110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Facilitation of Definitive Cancer Diagnosis With Quantitative Molecular Assays of BRAF V600E and TERT Promoter Variants in Patients With Thyroid Nodules.
    Fu G; Chazen RS; Monteiro E; Vescan A; Freeman JL; Witterick IJ; MacMillan C
    JAMA Netw Open; 2023 Jul; 6(7):e2323500. PubMed ID: 37505499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF
    Nasirden A; Saito T; Fukumura Y; Hara K; Akaike K; Kurisaki-Arakawa A; Asahina M; Yamashita A; Tomomasa R; Hayashi T; Arakawa A; Yao T
    Virchows Arch; 2016 Dec; 469(6):687-696. PubMed ID: 27718012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of ultrasonographic/clinical profile, cytology, and BRAF V600E mutation evaluation in thyroid nodule screening for malignancy: a prospective study.
    Rossi M; Buratto M; Bruni S; Filieri C; Tagliati F; Trasforini G; Rossi R; Beccati MD; Degli Uberti EC; Zatelli MC
    J Clin Endocrinol Metab; 2012 Jul; 97(7):2354-61. PubMed ID: 22535974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presence of TERT ± BRAF V600E mutation is not a risk factor for the clinical management of patients with papillary thyroid microcarcinoma.
    Lee J; Ha EJ; Roh J; Kim HK
    Surgery; 2021 Sep; 170(3):743-747. PubMed ID: 33952391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular genotyping of follicular variant of papillary thyroid carcinoma correlates with diagnostic category of fine-needle aspiration cytology: values of RAS mutation testing.
    Lee SR; Jung CK; Kim TE; Bae JS; Jung SL; Choi YJ; Kang CS
    Thyroid; 2013 Nov; 23(11):1416-22. PubMed ID: 23590130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma.
    Paek SH; Kim BS; Kang KH; Kim HS
    World J Surg Oncol; 2017 Nov; 15(1):202. PubMed ID: 29132392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of FNAC, BRAF mutation, and intraoperative frozen section in surgical decision-making of thyroid nodules.
    Zhu Z; Su C; Chen G; Wan F; Jin M; Duan X; Wang Y; Wang G
    Diagn Cytopathol; 2023 Jul; 51(7):441-448. PubMed ID: 37042168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.